Bulls REASONS TO BUY
May 22, 2013
(Stock Blog Hub, 12/11/12)
Baxter International (BAX) recently revealed critical Phase I/III study outcomes analyzing the efficacy and safety of BAX 326. This is an investigational recombinant factor IX protein, which...(read more)
(Wealth Daily, 12/5/12)
Baxter International Inc. (NYSE: BAX) the world's second-largest dialysis equipment manufacturer, is set to purchase the world's third-largest...
(Wealth Daily, 9/19/12)
Rethink Robotics' robot Baxter is slow-moving in order to be safe around humans...
Baxter International (BAX) Company Overview
Headquartered in Deerfield, Illinois, Baxter International (NDAQ: BAX) is a global diversified medical products and services company with expertise in medical devices, pharmaceuticals, and biotechnology, used to treat complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, and trauma. With 48,000 employees, manufacturing centers in 27 countries, and operations in over 100 countries, the firm operates in three business segments: BioScience (pharmaceuticals derived from blood plasma), Medication Delivery (products for intravenous therapy), and Renal (dialysis equipment and solutions for patients with kidney failure).
Led by hemophilia drug ADVATE and immune deficiency drug IVIG, BioScience has been Baxter's fastest-growing segment in recent years. The Renal segment specializes in dialysis machines for people with terminal kidney disease or failure and has achieved high growth in emerging markets where many people are under-treated.(Read more at Wikinvest )
What's in this BAX analysis on Wikinvest...